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Abstract In 2006, under the auspices of The Spanish
Research Group for Ovarian Cancer (Spanish initials GE-
ICO), the first ‘‘Treatment Guidelines in Ovarian Cancer’’
were developed and then published in Clinical and Trans-
lational Oncology by Poveda Velasco et al. (Clin Transl
Oncol 9(5):308–316, 2007). Almost 6 years have elapsed
and over this time, we have seen some important devel-
opments in the treatment of ovarian cancer. Significant
changes were also introduced after the GCIG-sponsored
4th Consensus Conference on Ovarian Cancer by Stuart
et al. (Int J Gynecol Cancer 21:750–755, 2011). So we
decided to update the treatment guidelines in ovarian
cancer and, with this objective, a group of investigators of
the GEICO group met in February 2012. This study sum-
marizes the presentations, discussions and evidence that
were reviewed during the meeting and during further dis-
cussions of the manuscript.
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Methodology
During one and a half-day meeting, several topics on the
management of ovarian cancer (OC) were reviewed by a
panel of experts from GEICO about different areas. Each
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presentation covered the most accurate evidence about the
specific topic and it was followed by a discussion in the
panel of experts. The topics that were reviewed included:
diagnosis, screening hereditary ovarian cancer, pathology,
molecular biology, surgery of initial and advanced stages,
systemic therapy of early and advanced stages, therapy of
recurrent disease and strategies for the future in OC
management.
To assign a level of evidence and a grade of recom-
mendation to the different statements of this treatment
guideline, it was decided to use the Infectious Diseases
Society of America-US Public Health Service Grading
System for ranking recommendations in clinical guidelines
to determine the quality of evidence and strength of rec-
ommendation in each of the consensus recommendations
(Table 1) [3].
When no unanimous consensus was achieved about the
level of recommendation, an explanation of the different
arguments was included in the manuscript.
Finally, a draft of the treatment guideline was sent to all
the participants and also to other GEICO members for
revision, discussion and final approval.
Diagnosis
Patients suspected to have adnexal mass
Transvaginal ultrasound (US) is considered the first-line
imaging technique to be performed and includes mor-
phology and color Doppler mapping. This will help
determine its site of origin and characterize it as potentially
benign or malignant. Transvaginal US has a high negative
predictive value and is an excellent tool for ruling out OC
[Quality of evidence, strength of recommendation: II, B]
[4, 5].
CA 125, although not specific for EOC, is the most
frequently used tumoral marker in the diagnostic process of
an ovarian mass. It is elevated in 83 % of women with
EOC but in only 50 % of those with stage I disease. In the
presence of carcinomatosis, a proportion of CA 125/CEA
[25 suggest ovarian cancer origin, and the opposite result,
intestinal tumor. In young woman (\35 years), additional
tumor markers like inhibin, AFP or B-hCG, should be
measured if clinically indicated [3, 6].
It has been suggested that serum HE4 and CA 125 along
with the algorithm ROMA (risk of ovarian malignancy)
may be useful for determining whether a pelvic mass is
malignant or benign. Nevertheless, a recently published
study found that subjective assessment by US performed
better than the ROMA and RMI (risk of malignancy index)
in discriminating malignant from benign masses [7].
Patients with suspected ovarian cancer
Surgical staging is the gold standard in OC and cannot be
replaced by imaging techniques particularly in the detec-
tion of small peritoneal deposits. However, there is a trend
toward increased use of imaging prior to surgical staging
and cytoreduction to plan the surgical approach [8].
The staging accuracy of computed tomography (CT) or
magnetic resonance imaging (MRI) is reported to be
70–90 %, although few studies comparing the accuracy of
both techniques are available. The accuracy of detection of
peritoneal implants with both CT and MRI is dependent on
their location, size and the presence of ascites. Contrast-
enhanced CT is the imaging modality of choice for staging
of ovarian cancer, with the MRI being used as a problem-
solving tool. In stages III and IV, the use of US is not
recommended as staging modality due to its lower sensi-
tivity to detect peritoneal metastases and other sites of
disease compared to CT and MRI. CT can also be used to
define disease extent that may help to evaluate the suit-
ability for upfront cytoreductive surgery or for neoadjuvant
chemotherapy. Although criteria for non-resectability vary
widely between institutions and individual surgeons
expertise, there are some preoperative imaging indicators,
Table 1 Infectious Diseases Society of America-US Public Health
Service Grading System for ranking recommendations in clinical
guidelines [3]
Category,
grade
Definition
Strength of recommendation
A Good evidence to support a recommendation for use
B Moderate evidence to support a recommendation for use
C Poor evidence to support a recommendation
D Moderate evidence to support a recommendation against
use
E Good evidence to support a recommendation against use
Quality of evidence
I Evidence from C1 properly randomized, controlled trial
II Evidence from C1 well-designed clinical trial, without
randomization; from cohort or case-controlled analytic
studies (preferably from[1 center); from multiple time
series; or from dramatic results from uncontrolled
experiments
III Evidence from opinions of respected authorities,
based on clinical experience, descriptive studies,
or reports of expert committees
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like the following: tumor deposits greater than 2 cm in the
porta hepatis, diaphragmatic deposits, disease in the inter-
segmental fissure of the liver, lesser sac, small bowel
mesentery and gastrosplenic ligament, parenchymal hepa-
tic disease, and suprarenal aortic lymphadenopathy. How-
ever, this is highly dependent on the skills of the surgeon
and the extension of the tumor. For instance, one solitary
intraparenchymal liver metastasis can be potentially
resected, and a diaphragmatic implant can be resected by
well-trained surgeons. This fact and increasing surgical
expertise in cytoreduction imply that preoperative CT
predictors should be used with caution when assessing
feasibility of primary cytoreduction [7].
Image-guided biopsy can be performed under US or CT
guidance if, on the basis of imaging, the patient would
benefit from neoadjuvant chemotherapy as histological
confirmation of OC is mandatory. It is also essential prior
to surgery if there is some clinical concern about the pri-
mary origin of the disease [7].
If there is uncertainty in the staging by radiological
techniques, laparoscopic evaluation to select patients to
cytoreductive surgery would play a great role in identifying
patients unsuitable for optimal resection. Tissue for defin-
itive histological diagnosis can also be obtained at the time
of this procedure [III, B] [9].
Positron emission tomography using fluorodeoxyglu-
cose (FDG-PET/CT) as staging tool in newly diagnosed
advanced stages has not yet been fully determined.
However, it provides an accurate assessment of disease in
areas difficult to assess for metastases by CT and MRI
like mediastinum, supraclavicular region, or small peri-
toneal implants. Normal-sized aortic lymph nodes with
malignant involvement may also be identified by PET–CT
[7].
Gastrointestinal (GI) workup in patients with diffuse
carcinomatosis and GI symptoms may be indicated,
including upper and/or lower endoscopy.
Since breast cancers can metastasize to the ovaries,
more frequently when there is a bilateral involvement,
mammography can help rule out this possibility and should
be included in the preoperative workup for women older
than 40 years who have not had one in the preceding
6–12 months.
Chest imaging, tumor markers, complete blood count
and chemistry profile with liver and renal function are also
part of the preoperative workup.
Screening/early detection of ovarian cancer
When the disease is detected early, the 5-year survival is in
excess of 90 % and this constitutes the rationale for the
premise that detecting the disease in early stage may affect
long-term survival. Although it has been shown that
screening can detect the OC earlier and provide a survival
benefit in the screening group, there is limited evidence
that this can affect mortality from the disease and published
data about it are conflicting [5].
In the largest trial UKTOCS using sequential CA 125
and transvaginal US, a survival advantage was achieved in
the screened population compared with the control group.
It was the consequence of a stage shift (82 % of screen-
detected cancers were early stage compared with 34 % of
those from the control group, p \ 0.0001). Final results of
this study are awaited in 2015 before definitive conclusions
can be drawn [10, 11].
On the contrary, the PLCO study reported no mortality
benefit with OC screening, although some concerns have
been raised about trial design [12]. Despite the generalized
belief that OC lacks obvious warning symptoms, a recent
review of a large number of publications suggest that up to
90 % of women experience symptoms before their diag-
nosis. A symptom index has been developed and when
combined with CA 125 and HE4 showed an increase in
specificity to 98 %.
Among high-risk women (mainly mutations in the
BRCA1/2 genes), the sensitivity and effectiveness of
screening are yet to be established. Several trials are still
under way and their results will come out during the next
years [13].
Hereditary ovarian cancer
Approximately 13 % of EOCs are associated with inheri-
tance of an autosomal dominant genetic aberration, which
leads to cancer predisposition with a moderate to high
penetrance [14]. BRCA1 and BRCA2 proteins are essential
to the homologous recombination DNA repair mechanism,
in recognizing double-strand breaks.
Currently, Dragon Database for Exploration of Ovarian
Cancer Genes (DDOC) contains a set of 379 human genes
experimentally verified as involved in OC [15]. Table 2
shows the best-known genes [16].
The estimated lifetime risk is 1 case in every 70 women,
which is a 1.4 % lifetime incidence [17]. This estimated
lifetime risk increases to 3 % in a second-degree relative,
to 5 % in a first-degree relative, and up to 9 % in Lynch
syndrome (hereditary nonpolyposis colorectal cancer). It
reaches 39–60 % in BRCA1 mutation and 11–30 % in
BRCA2 mutation [18].
Oncologists have a crucial opportunity to utilize risk
assessment and cancer prevention strategies to interrupt the
initiation or progression of OC in cancer survivors and
individuals at high risk of developing cancer [19]. The
Amsterdam II criteria [20] and Revised Bethesda Guide-
lines [21] (Table 3) can be used to identify the criteria for
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referring a patient to the genetic counseling unit (GCU),
based on three questions (Table 4). A detailed family his-
tory of cancer taken at the first visit with the oncology
provider, and based on the following three questions, can
raise the suspicion of a hereditary cancer syndrome and be
referred to the GCU [II, A] [22].
Two hereditary syndromes, namely hereditary breast
and ovarian cancer (HBOC) and Lynch syndrome, with
mutations in BRCA1/2 genes and mismatch repair genes,
respectively, have been identified (Table 5).
Hereditary nonpolyposis colorectal cancer (HNPCC) or
Lynch syndrome is a common, autosomal dominant syn-
drome characterized by early onset (average age at onset
\45 years), the development of neoplastic lesions in a
variety of tissues (colon, gastrointestinal tract, ovary, and
uterus) and microsatellite instability (MSI). For carriers of
Lynch syndrome, the estimated lifetime risk of OC is
9–12 %.
HBOC is characterized by an increased susceptibility to
breast cancer occurring at a young age, bilateral breast
cancer, male breast cancer, and OC at any age. Other
cancers such as prostate cancer, pancreatic cancer, gastro-
intestinal cancers, melanoma and laryngeal cancer occur
more frequently in HBOC families. Hereditary site-specific
breast cancer families are characterized by early-onset
breast cancer with or without male cases, but without
ovarian cancer. For this consensus, both will be referred
collectively as hereditary breast and/or ovarian cancer.
Germline mutations in the BRCA1 and BRCA2 genes are
Table 3 The Revised Bethesda Guidelines and Amsterdam II criteria [21, 25]
The Revised Bethesda Guidelines for testing colorectal tumors for microsatellite instability (MSI)
Tumors from individuals should be tested for MSI in the following situations:
1. Colorectal cancer diagnosed in a patient who is less than 50 years of age
2. Presence of synchronous, metachronous colorectal, or other HNPCC-associated tumors,a regardless of age
3. Colorectal cancer with the MSI-Hb histologyc diagnosed in a patient who is less than 60 years of aged
4. Colorectal cancer diagnosed in one or more first-degree relatives with an HNPCC-related tumor, with one of the cancers being diagnosed
under age 50 years
5. Colorectal cancer diagnosed in two or more first- or second-degree relatives with HNPCC-related tumors, regardless of age
Amsterdam II Clinical criteria for families with Lynch syndrome
Each of the following criteria must be fulfilled:
3 or more relatives with an associated cancer (colorectal cancer, or cancer of the endometrium, small intestine, ureter or renal pelvis)
2 or more successive generations affected
1 or more relatives diagnosed before the age of 50 years
1 should be a first-degree relative of the other two
Familial adenomatous polyposis (FAP) should be excluded in cases of colorectal carcinoma
Tumors should be verified by pathologic examination
a Hereditary nonpolyposis colorectal cancer (HNPCC)-related tumors include colorectal, endometrial, stomach, ovarian, pancreas, ureter and
renal pelvis, biliary tract, and brain (usually glioblastoma as seen in Turcot syndrome) tumors, sebaceous gland adenomas and keratoacanthomas
in Muir–Torre syndrome, and carcinoma of the small bowel [26]
b MSI-H, microsatellite instability-high, in tumors refers to changes in two or more of the five National Cancer Institute recommended panels of
microsatellite markers
c Presence of tumor infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, mucinous/signet-ring differentiation, or medullary growth
pattern
d There was no consensus among the Workshop participants on whether to include the age criteria in guideline 3 above; participants voted to
keep less than 60 years of age in the guidelines
Table 2 Genes implicated in hereditary ovarian carcinoma
FA-BRCA pathway genes HBOC
BRCA1
BRCA2
RAD51C Low penetrance genes
RAD51D
BRP1
BARD1
CHEK2
MRE1 1A
NBN
PALB2
RAD50
Mismatch repair genes Lynch syndrome
MLH1
MSH2
MSH6
PMS2
Other genes Li–Fraumeni syndrome
TP53
HBOC hereditary breast and ovarian cancer
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responsible for cancer susceptibility in the majority of
HBOC families.
There is a high rate of tubal intraepithelial carcinoma
(TIC) in high-risk women undergoing risk-reducing sal-
pingo-oophorectomy. Recent studies have documented that
up to 59 % of high-grade pelvic (non-uterine) serous car-
cinomas are associated with serous TICs. This is consistent
with the hypothesis that the fallopian tube is the source of a
majority of these tumors [23]. Approximately 30 % of
women with fallopian tube cancer have a mutation in
BRCA1 or BRCA2 [24, 25]. In women with BRCA1 and
BRCA2 mutations, the use of risk-reducing mastectomy
was associated with a lower risk of breast cancer; risk-
reducing salpingo-oophorectomy was associated with a
lower risk of breast and ovarian cancer [32].
Patients with invasive EOC with a germline mutation in
BRCA1 or BRCA2 were associated with improved 5-year
overall survival. BRCA2 carriers had the best prognosis.
This may be due to distinct clinical behavior and/or to a
better response to chemotherapy.
Primary prevention by detecting more women at high
risk for the disease development by applying new methods
of prevention like risk-reducing surgery is perhaps a more
useful strategy for reducing mortality for OC patients. As
mentioned before, there is accumulating evidence sug-
gesting that serous neoplasia originates in secretory fallo-
pian tube surface epithelium. This intraepithelial lesion has
been found in about 43 % of women with advanced serous
cancers, so this finding may potentially serve as a carcin-
ogenic marker. Its identification in women at uncertain
risk by means of minimally invasive methods or with
salpingectomy at the time of other major surgical proce-
dures in women who have completed their childbearing
may be a reasonable strategy that deserves investigation
[26–28].
Pathology and molecular genetics
Several studies have shown that OC is not a single disease,
but instead is composed of a diverse group of tumors that
can be classified based on distinctive morphologic and
molecular genetics features [29]. Additionally, the various
subtypes have a different natural behavior and prognosis
[33].
Based on light microscopy and molecular genetics, they
can be subdivided into at least five main subtypes [30],
classified by cell type into serous, mucinous, endometrioid,
clear cell, and Brenner (transitional) tumors corresponding
to different types of epithelia in the organs of the female
reproductive tract. Once grouped by cell type, the tumors
can be further subdivided into those that are clearly benign
(cystadenomas), those that are clearly malignant (carcino-
mas), and those that have features somewhere between
these two, variably called ‘‘atypical proliferative’’ tumors,
tumors of ‘‘low malignant potential’’ or tumors of ‘‘bor-
derline’’ malignancy. These subtypes show differences in
epidemiological and genetic risk factors, precursor lesions,
spreading patterns, molecular events during oncogenesis,
response to chemotherapy and outcome.
Histopathological findings strongly suggest that there is
a morphological and biological spectrum which starts with
a benign serous cystadenoma/adenofibroma, and continues
from a proliferative tumor (atypical proliferative serous
tumor) to a non-invasive carcinoma (non-invasive micro-
papillary serous carcinomas), ending with an invasive low-
grade serous carcinoma (LGSC) (invasive micropapillary
serous carcinomas). Type I tumors (low-grade serous car-
cinoma, mucinous carcinoma, endometrioid carcinoma,
malignant Brenner tumor, and clear cell carcinoma)
develop in a stepwise manner from well-recognized pre-
cursors, namely borderline tumors that in turn develop
from cystadenomas and adenofibromas [31]. Type II
tumors are high grade at presentation and are currently
classified as high-grade serous carcinoma (HGSC), malig-
nant mixed mesodermal tumors (carcinosarcomas), and
undifferentiated carcinoma [32]. High-grade serous his-
tology is more frequent in advanced stage. HGSC and
LGSC have different histology, molecular genetic altera-
tions and biology [33] (Table 6). HGSC displays TP53
mutations in over 90 % of cases and rarely harbors the
mutations that are found in the type I tumors (KRAS and
BRAF). They are also characterized by potential aberra-
tions in BRCA1 and BRCA2, in up to 50 % of cases [34].
Table 5 Mutations in BRCA1/2 genes and mismatch repair genes in
HBOC and Lynch syndrome
HBOC Lynch syndrome
Genes BRCA1 and
BRCA2
MLH1, MSH2, MSH6 and
PMS2
Increased
risk of
cancer
Breast, ovarian,
pancreatic,
prostate
Colon, uterine, ovarian, other
cancers of the digestive tract
HBOC hereditary breast and ovarian cancer
Table 4 Family history in three questions
Family history in three questions
1. How old was the diagnosis?
2. First-degree relatives
HBOC
LYNCH
3. Second-degree relative
HBOC hereditary breast and ovarian cancer
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Mucinous borderline tumors are classified into two dif-
ferent clinicopathological types: intestinal (85 % of cases)
and endocervical (15 %). Bilateralism, in the case of a
mucinous tumor, suggests that the possibility of adeno-
carcinoma metastasis, generally of gastrointestinal or
pancreatic origin, should be ruled out. Moreover, bilateral
ovarian tumors accompanied by pseudomyxoma peritonei
tend to be of appendicular origin [35]. Immunohisto-
chemical study with cytokeratin 7 and 20 can help in
defining the origin of the lesion (EOC: CK7?/CK20-;
metastasis: CK7-/CK20?).
Clear cell carcinomas (CCCs) constitute a spectrum of
tumors of differing degrees of malignancy which are
characterized by being formed by clear hobnailed, eosin-
ophilic cells. Adenofibromas and clear cell borderline
tumors are very uncommon. Given that CCCs frequently
show a mixture of growth patterns and nuclear atypia, they
are tumors that do not tend to progress from a histological
point of view [36].
In CCCs, molecular alterations similar to those of EOCs
have been described, but with a different frequency: beta-
catenin mutations (5 %), PTEN (5–8 %), K-RAS
(15–30 %), and MSI (5 %) [37–39].
Ovarian clear cell and endometrioid carcinomas may
stem from endometriosis. ARID1A mutations were
observed in 55 of 119 ovarian CCCs (46 %), 10 of 33
endometrioid carcinomas (30 %), and none of 76 high-
grade serous ovarian carcinomas [40].
Identifying patients who would benefit from particular
targeted therapies is an important objective. The first step
in developing tools to improve cancer control for OC is to
recognize that OC represents many diseases [41]. Addi-
tionally, it is highly recommended that human biospeci-
mens for translational studies be available from clinical
trials.
Surgical treatment
Surgery is the cornerstone in treatment of ovarian cancer.
All patients with newly diagnosed disease who are fit for
surgery should be considered for a full staging laparotomy
for accurate information on disease and histology. This is
important for predicting prognosis and decision of post-
surgical therapy. Based on published improved outcomes,
it is recommended that a gynecologic oncologist surgeon
perform the primary surgery [II, A] [42]. Types of surgery
for OC may include: primary surgery for staging and cy-
toreduction, interval debulking surgery (IDS); secondary
cytoreduction, second look operation, and palliative
surgery.
Early disease (clinical stage I/II)
The aim was proper staging of disease and removal of all
macroscopic tumor. Surgery can be performed either
preferably by laparotomy, which is the most accepted
procedure, or minimally invasive surgery in selected
patients if performed by an experienced gynecologic
oncologist. Procedures must comprise thorough inspection
and palpation of all peritoneal surface, total hysterectomy
and bilateral salpingo-oophorectomy (TH ? BSO), omen-
tectomy, pelvic and bilateral aortic lymphadenectomy up to
the renal vessels, biopsies of pelvic peritoneum, paracolic
gutters and right subdiaphragmatic area, sampling of
ascites or peritoneal washing for cytology (when no ascites
is found). Appendectomy is recommended in mucinous
tumors [43].
Several updated studies have concluded that complete-
ness of surgical staging in patients with early stage was
significantly associated with better outcomes. The 2010
GCIG consensus stated that surgical staging should be
mandatory and be performed by a gynecologic oncologist
[II, A] [2]. Under-staged patients in previous surgery
should be re-staged according to the same surgical princi-
ples mentioned above. The same principle should be
applied for patients with poorly differentiated tumor, clear
cell histology, and stage IC due to ovarian surface involve-
ment [44].
For a young patient (\40 years) who wishes to maintain
fertility, a unilateral salpingo-oophorectomy may be ade-
quate for selected stage I tumors (Ia and Ic due to intra-
operative rupture but with negative cytology, grade 1 or 2,
but not stage IB) in addition to the staging procedure. After
fulfilling their wishes of fertility, salpingo-oophorectomy is
recommended [III, B]. The practice of carrying out a
wedge biopsy on a grossly normal contralateral ovary
should be discouraged. If the histology is of endometrioid
type, an endometrial biopsy should be performed to rule
out a concurrent endometrial cancer. Most studies have
Table 6 High-grade serous carcinoma (HGSC) and low-grade serous
carcinoma (LGSC) differences
HGSC LGSC
Risk factors BRCA 1/2 ?
Precursor lesions Tubal intraepithelial
carcinoma
Serous borderline
tumor
Pattern of spread Very early
transcoelomic
Transcoelomic
spread
Molecular
abnormalities
BRCA, p53 BRAF, KRAS
Ki-67 High Low
Chemosensitivity High Intermediate
Estrogen receptor 2/3 ?
Prognosis Poor Intermediate
Median age at
presentation
Higher Lower
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found that conservative treatment is suitable for patients
with serous, mucinous, or endometrioid carcinoma but not
for patients with high-risk factors such as clear cell or
poorly differentiated carcinoma [45, 46].
Advanced disease (III–IV)
The standard treatment of advanced OC is cytoreductive
surgery followed by platinum-based combination chemo-
therapy. Although the ultimate goal is cytoreduction to
microscopic disease by removing all visible disease, suc-
cessful cytoreduction to small-volume disease (\1 cm)
increases the frequency of complete response and overall
survival [II, A] [47–49]. According to the 2010 OC Con-
sensus conference held in Vancouver, the term ‘‘optimal’’
cytoreduction should be reserved for those with no mac-
roscopic residual disease [2].
The maximal surgical effort may comprise sometimes
the following procedures: TAH ? BSO (supracervical
hysterectomy is also appropriate in some circumstances),
omentectomy, radical pelvic dissection, bowel resection,
diaphragm or other peritoneal surface stripping, splenec-
tomy, partial hepatectomy, partial gastrectomy or cystec-
tomy, distal pancreatectomy, or lymphadenectomy (bulky
or suspicious lymph nodes resection). If complete cytore-
duction is achieved, lymphadenectomy may increase
overall survival [55].
Some contraindications for the outcome of this ‘‘maxi-
mum’’ effort surgery have been pointed out such as the
following: poor performance status (Karnofsky \40),
mesentery root involvement, extra-abdominal visceral
disease, multiple intraparenchymal liver metastases, or
intestinal massive-serosal carcinomatosis [II, A]. Never-
theless, as surgery on advanced OC evolves, some of these
contraindications are being overcome [50, 51].
Delayed primary surgery after neoadjuvant chemother-
apy or IDS is an option for selected patients with stage IIIC
and IV. Despite the results of a recent randomized con-
trolled trial, this therapeutical plan remains controversial.
According to some authors, neoadjuvant chemotherapy
followed by IDS should be reserved for patients who do not
have access to gynecologic or surgical oncologist, cannot
tolerate the procedure, and/or for whom optimal cytore-
duction is deemed not feasible by an experienced surgical
team. The goal of this surgery should be the same as in
primary surgery and comprise the same procedures if
necessary [52, 56].
Patients with low volume (\1 cm) of residual disease
after upfront primary debulking surgery are potential can-
didates for intraperitoneal (IP) chemotherapy and, in these
patients, consideration should be given to placement of an
IP catheter with initial surgery [53].
Systemic therapy in first line
Early stages
The results of studies published in the last 10 years support
adjuvant treatment with chemotherapy after surgery in
most patients showing early stages of epithelial ovarian
cancer [54–58]. Only low-risk patients (stages IA/B Grade
1 and no clear cell histology) with correct surgical staging
require observation exclusively, as long-term survival after
surgery is above 90 % [59].
Adjuvant treatment with chemotherapy after surgery is
indicated in high-risk early stages (IA and IB Grade 3,
clear cell tumors and any grade of stages IC and IIA) [I, A].
However, there is no consensus on the need to treat stages
IA/B Grade 2. For these cases, both observation and
adjuvant treatment can be regarded as valid options (Fig. 1)
[1]. The ICON 1 [62] and ACTION [60] studies, as well as
the combined analysis of both [61], support the use of
adjuvant chemotherapy in early stages with a high risk of
Stages IA-IB 
Grade 2Grade 1 Grade 3, clear cells 
Observation Adjuvant chemotherapy with carboplatinum* 
Stages IC-IIA 
Follow-up 
Fig. 1 Adjuvant therapy in
stage I and stage IIA epithelial
ovarian cancer
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relapse, as an improvement is seen in both disease-free
survival and overall survival (OS) when adjuvant platinum-
based chemotherapy is given.
As yet, there are no data from comparative studies on
these stages to determine the value of adding paclitaxel to
platinum. Chemotherapy must at least include carboplati-
num (AUC 5–7.5). The GOG-157 trial compared the
administration of 3 cycles of paclitaxel (175 mg/m2 over
3 h) and carboplatin (AUC 7.5) versus 6 cycles of the same
combination in patients with stage I optimally staged. The
risk of recurrence was 33 % lower for patients treated with
6 cycles. However, this difference did not reach statistical
significance (95 % CI 0.49–1.16). Additionally, the 6-cycle
arm was associated to a higher hematological toxicity and
neurological grade 2–4 toxicity (28 vs. 13 %). Based on
this trial, the current standard chemotherapy in the adjuvant
setting consists of at least 3 cycles of paclitaxel and car-
boplatin [64].
Advanced stages
Conventional chemotherapy
The current therapeutic strategy generally recommended
for the treatment of advanced OC (IIc–IV) is optimal cy-
toreductive surgery followed by 6 cycles of paclitaxel and
carboplatin [61–63]. The recommendation to include pac-
litaxel with platinum was based on two large randomized
studies that established the superiority of the paclitaxel–
cisplatin combination versus cyclophosphamide–cisplatin
[64, 65]. Mature data maintain this results [70], and the
combined analysis showed survival benefits with the pac-
litaxel scheme [66]. Subsequently, three randomized stud-
ies that included over 1,500 patients compared paclitaxel–
cisplatin with paclitaxel–carboplatin; no differences were
found in response to progression-free survival (PFS), but
toxicity and tolerability profiles were better for the carbo-
platin-combination arms [67–69]. According to the 4th
Ovarian Cancer Consensus Conference [2], the standard
treatment should include paclitaxel (175 mg/m2) and car-
boplatin (AUC 5–7.5) every 3 weeks for 6 cycles [I, A].
The data from the MITO-2 randomized, multicenter clini-
cal trial conducted by the Multicenter Italian Trials in
Ovarian (MITO) Cancer group indicate that the activity of
carboplatin and pegylated liposomal doxorubicin (PLD) is
similar to that of standard first-line therapy with carbo-
platin/paclitaxel in advanced ovarian cancer. Moreover, in
terms of safety, the study group had a lower incidence of
peripheral neuropathy (15 %) and alopecia (14 %) than the
control group (47 and 63 %, respectively) [70]. However,
this was a study with a design of superiority that did not
meet its primary endpoint. For this reason, it should be
considered a negative study that has not changed the
standard of care. However, it can be considered a treatment
option for patients not eligible to receive taxol.
Triplet and doublet chemotherapies
Various treatment strategies have been applied with a view
to improving the prognosis of these patients. One is the
addition of one or more drugs without cross resistance with
the therapy which up to now has been considered standard
(carboplatin–paclitaxel). Three studies have been published
in this area evaluating the addition of a third drug in triple
or sequential form (epirubicin, gemcitabine, topotecan or
PLD) [71–73].
Unfortunately, none has been shown to be of any
advantage. Adding one or more drugs only signifies greater
toxicity. The administration of a third or more drugs is not
therefore recommended at present [I, E].
Maintenance chemotherapy
In an effort to improve the modest results obtained in
patients with suboptimal debulking, trials have been con-
ducted with consolidation or maintenance chemotherapy.
To date, none of the treatments administered following
initial induction with platinum/paclitaxel have shown to
improve survival [74–78].
Neoadjuvant chemotherapy (NAC)
A meta-analysis examined the effectiveness of NAC with
platinum and IDS for advanced ovarian cancer, including
835 patients from 51 studies. Patients who had undergone
IDS after an attempt at primary surgery were found to have
survived for less time than those who had primary surgery.
However, the review only included phases I to II and ret-
rospective studies [79]. This observation was the back-
ground for a study conducted by the European Organisation
for the Research and Treatment of Cancer (EORTC)
Gynaecological Cancer Group, in conjunction with the
National Cancer Institute of Canada (NCIC) Clinical Trials
Group (EORTC-55971) between 1998 and 2006 that
included 670 women with stages IIIC or IV ovarian cancer
[80]. The women were randomized to primary debulking
surgery, followed by at least six cycles of platinum-based
chemotherapy or three cycles of NAC, also platinum based,
followed by IDS, and by at least three more cycles of
platinum-based chemotherapy. The median OS after pri-
mary debulking surgery was 29 months, compared to
30 months for the patients assigned to NAC. The hazard
ratio for death in the group assigned to NAC followed by
interval debulking, as compared with the group assigned to
primary debulking surgery followed by chemotherapy, was
0.98. The subgroup of patients who had optimal debulking
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(\1 cm) after primary debulking surgery or NAC followed
by IDS had the best median OS [92].
Despite these results, NAC is still a controversial issue.
Some concerns have risen from the quality of the surgery
performed in this trial and the wide use of NAC even in
patient candidate for optimal upfront debulking surgery. In
conclusion, NAC should be reserved for those who cannot
tolerate PDS and/or for whom optimal cytoreduction is not
feasible after an adequate evaluation performed by a sur-
gical team well trained on cytoreduction [I, B] [59].
Dose-dense regimen
A Japanese study evaluated the weekly (dose-dense)
administration of paclitaxel in patients with advanced
ovarian cancer. This was a phase III study which included
631 patients with stage II–IV (82 % were stage III–IV)
[81]. They were randomized to receive paclitaxel every
3 weeks at the dose of 185 mg/m2 versus weekly paclit-
axel (dose-dense regimen) at 80 mg/m2 for 3 weeks. Both
arms received carboplatin at an AUC of 6 every 3 weeks.
According to the published results, there was a statistically
significant improvement in PFS (28 vs. 17.2 months,
p = 0.015) in favor of the dose-dense administration arm.
After long-term follow-up, at 6.4 years of median, it
continues to show a highly statistically significant
improvement in median PFS in favor of the dd-TC group
compared with the c-TC group [28.1 vs. 17.5 months,
hazard ratio (HR) 0.75, 95 % CI 0.62–0.91, p = 0.0037],
and also a benefit in the 5-year overall survival rate (58.7
vs. 51.1 %, HR 0.79, 95 % CI 0.63–0.99) [82] [I, B]. This
interesting strategy should be confirmed in the Caucasian
population, as the Japanese population may have genetic
differences that could influence the pharmacokinetics or
pharmacodynamics of the weekly schedule. In fact, tox-
icity in the Japanese population was significant with 36 %
of patients discontinuing therapy due to side effects. Two
European trials are dealing with this topic, MITO 7 and
ICON 8, however, they have not been presented and we do
not have definitive data for a formal recommendation of
this schedule to Caucasian patients with advanced ovarian
cancer.
Intraperitoneal chemotherapy (IP CT)
IP chemotherapy has certain clinical and pharmacological
advantages over intravenous chemotherapy in patients with
EOC limited to the abdominal cavity, who have had opti-
mal debulking surgery. Three large randomized studies
found improvements in PFS and OS (Table 7) [83, 84, 93].
The last and most important of them was the GOG-172
study, published in 2006 by Dr. Armstrong [85] that
included 415 patients with stage III and residual tumor
B1 cm. The patients were randomized to receive either
cisplatin 75 mg/m2 i.v. plus paclitaxel 135 mg/m2 i.v. by
continuous infusion over 24 h every 3 weeks for 6 cycles
or paclitaxel 135 mg/m2 i.v. followed by cisplatin 100 mg/
m2 i.p. plus paclitaxel 60 mg/m2 i.p. on day 8 every
3 weeks for 6 cycles. As with the previous study, patients
in the IP CT arm had longer PFS (23.8 vs. 18.3 months,
p = 0.05) and OS (65.6 vs. 49.7 months, p = 0.03).
A number of meta-analyses and systematic reviews have
analyzed the above studies together and have categorically
confirmed the results in terms of benefits over PFS and OS.
However, what they also show is an increase in toxicity,
especially fever, fatigue, gastrointestinal problems, infec-
tion, pain, deafness and metabolic and neurological
abnormalities [86].
IP CT has therefore shown to be superior to i.v. CT and
is another standard option in the management of patients
with stage III and residual tumor B1 cm, even taking into
account the technical issues with this method and the
toxicity which at present limits its routine use [I, A].
Because of these difficulties, IP CT may be an option only
for selected patients and selected centers.
Antiangiogenic therapy
Two phase III trials (GOG 0218 and ICON7) [87, 88] have
shown that bevacizumab may be beneficial when added to
Table 7 Summary of studies in intraperitoneal chemotherapy
Study Control regimen Experimental regimen Eligible
patients
No. of
patients
SWOG 8501/GOG
104, Alberts et al.
[83]
Cisplatin, 100 mg/m2 i.v.;
cyclophosphamide, 600 mg/m2 i.v.
q 3 weeks 9 6
Cisplatin. 100 mg/m2 i.p.; cyclophosphamide, 600 mg/
m2 i.v. q 3 weeks 9 6
Stage III,
B2 cm
residual
546
GOG 114/SWOG
9227, Markman
et al. [84]
Cisplatin. 75 mg/m2 i.v.; paclitaxel,
135 mg/m2 24-h i.v. q 3 weeks 9 6
Carboplatin, AUC 9 i.v. q 28 days 9 2; cisplatin,
100 mg/m2 i.p.; paclitaxel, 135 mg/m2 24 h i.v. q
3 weeks 9 6
Stage III,
B1 cm
residual
462
GOG 172, Armstrong
et al. [85]
Cisplatin, 75 mg/m2 i.v.; paclitaxel,
135 mg/m2 24 h i.v. q 3 weeks 9 6
Paclitaxel, 135 mg/m2 24-h i.v.; Cisplatin, 100 mg/m2
i.p.; paclitaxel, 60 mg/m2 i.p. on day 8 q
3 weeks 9 6
Stage III,
B1 cm
residual
415
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standard chemotherapy with paclitaxel and carboplatin in
the first-line treatment of ovarian cancer.
Although both trials explored the same concept, there
were some differences in the design of the studies that it is
worth to be explained. The GOG-218 was a randomized
double blinded trial comparing bevacizumab with placebo
in three different arms: control arm with placebo during
chemotherapy followed by a maintenance phase with pla-
cebo, initiation group with bevacizumab added to chemo-
therapy followed by placebo and the throughout group with
bevacizumab added to initial chemotherapy followed by a
limited period of maintenance with bevacizumab. In the
ICON-7, the design was simpler, without placebo and with
only two arms, a control group with paclitaxel and carbo-
platin and the experimental arm with bevacizumab added
to paclitaxel–carboplatin followed by a maintenance period
with bevacizumab. There were also differences in the
duration of bevacizumab (15 months in GOG-218 vs.
12 months in ICON-7), the dose (15 mg/kg in GOG-218
vs. 7.5 mg/kg in ICON 7) and the population of patients
included (FIGO stage III–IV with macroscopic residual
disease after surgery in GOG-218 vs. FIGO stage I of high
risk to stage IV in ICON-7).
Both trials met their primary endpoint. In the COG-218,
the administration of bevacizumab concurrently with che-
motherapy followed by a maintenance phase of bev-
acizumab was associated with a significant increment in the
median PFS from 10.3 to 14.1 months (HR 0.71, 95 % CI
0.625–0.824, p \ 0.001). In the ICON-7, the median PFS
was 17.3 months in the standard-therapy group and
19.0 months in the bevacizumab group (HR 0.81, 95 % CI
0.70–0.94, p = 0.004).
Regarding tolerability, the main toxicity associated to
the administration of bevacizumab was hypertension,
which was grade 2 or higher in 22.9 and 18.9 % of patients
in the GOG-218 and ICON-7 trial, respectively. Moreover,
there were no significant differences in the rates of other
adverse events, including gastrointestinal perforation or
fistula, proteinuria of grade 3 or greater, neutropenia of
grade 4 or greater or febrile neutropenia, venous or arterial
thrombosis, and wound disruption.
Some additional exploratory analysis of both trials has
shown the following data:
1. A sensitive analysis of the GOG-218 censoring
progression by CA 125 and considering only the
patients who progressed by radiological imaging
showed that the median PFS was 12.0 months in the
control group but 18.0 months in the bevacizumab-
throughout group (HR 0.645, 95 % CI 0.551–0.756,
p \ 0.001).
2. The test for interaction performed in the ICON-7
suggests that the size of the effect of bevacizumab
differed between patients at high risk for progression
and the rest of the study population (p = 0.06). A sub-
analysis of patients at high risk of progression defined
by stage IV or stage III and suboptimal cytoreduction
with residual disease[1 cm showed that the estimated
median PFS was 10.5 months with standard therapy, as
compared with 16 months with bevacizumab (HR
0.73, 95 % CI 0.60–0.93; p = 0.002).
3. In a preliminary overall survival analysis of the ICON-
7 requested by regulatory agencies (the number of
events is not yet enough for this kind of analysis), it
was showed a HR for death in the bevacizumab group
of 0.85 (95 % CI 0.69–1.04, p = 0.11). However, the
test for interaction suggests that the size of the effect of
bevacizumab on overall survival differs between the
Ovarian Cancer Stages III and IV
Stage III without 
macroscopic residual 
disease:
Stage III with 
macroscopic residual 
disease <1cm:
Stage III-IV with residual 
disease >1cm:
• Intraperitoneal CT* 
[I,A]
• Intraperitoneal CT* 
[I,A]
• Carbo-paclitaxel-
bevacizumab [I,A]**
• Carbo-paclitaxel 
(three-weekly [I,A] vs. 
dense-dose [I,B])
• Carbo-paclitaxel-
bevacizumab [I,A]
• Carbo-paclitaxel 
(three-weekly [I,A] 
vs. dense-dose [IB])
• Carbo-paclitaxel 
(three-weekly [I,A] or 
weekly [I,B])
*Treatment recommended in patients who meet selection 
** Only for patients with macroscopic residual disease. 
Fig. 2 First-line systemic
treatment options in advanced
ovarian cancer
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patients at high risk for progression and the rest of the
women studied (p = 0.011). Among the women at
high risk for progression, the median overall survival
was 28.8 months in the standard-therapy group and
36.6 months in the bevacizumab group (HR 0.64,
95 % CI 0.48–0.85, p = 0.002).
Based on the available data, bevacizumab added to
initial chemotherapy followed by a maintenance period of
bevacizumab should be deserved for patients who, fol-
lowing standard surgery, are found to have macroscopic
residual disease [I, A]. According to exploratory analysis,
the benefit seems to be more significant in patients with
either stage III disease and residual disease[1 cm, or stage
IV disease.
Figure 2 shows the first-line systemic treatment options
in advanced ovarian cancer.
Therapy for relapsed ovarian cancer
Approximately 70–80 % of patients diagnosed with EOC
will suffer a relapse after receiving first-line chemotherapy
based on platinum and taxane. According to the Second
Consensus on OC held in 1998, a relapse was defined by
the presence of at least two of the following criteria [1]:
• Symptoms that may suggest disease (abdominal pain,
distension, etc.).
• Clinical or radiological evidence of disease.
• Progressive rise in CA 125, doubly confirmed by GCIG
criteria.
A trial by the Medical Research Council and European
Organisation for Research and Treatment of Cancer (MRC-
OV05) examined the consequences of early institution of
treatment for recurrence based exclusively on CA 125
criteria of progression versus treatment delayed until clin-
ical symptoms appeared [89]. The study concluded that
there was no survival benefit in the treatment of recurrent
OC based exclusively on a rise in the CA 125, and that it
anticipates a deterioration in the quality of life [I, A]. In the
last Ovarian Cancer Consensus Conference (OCCC), a new
classification of recurrent patients was proposed. Distinct
patient populations for clinical trial enrolment may be
considered according to interval from last platinum ther-
apy. Progression-free interval (PFI) is defined from the last
day of platinum until disease progression. The following
subgroups should be considered:
• Progression while receiving last line of platinum-based
therapy or within 4 weeks of last platinum dose.
• PFI since last line of platinum of \6 months.
• PFI since last line of platinum of 6–12 months.
• PFI since last line of platinum of [12 months.
The authors of this guideline strongly support the use of
the classification proposed in the OCCC.
Treatment of Distinct Sub-groups
PFI < 6 m PFI 6-12 m.
• Monotherapy*.
PFI > 12 m.
* A non platinum-based combination with trabectedine and PLD was studied in the OV-301 trial showing this 
(Defined by Progression Free-Interval) 
• MONOTHERAPY 
[IA]: PDL, Weekly 
Placlitaxel, 
Gemcitabine, 
Topotecan. 
• Single agent 
chemotherapy 
(weekly paclitaxel, 
PLD, topotecan) + 
bevacizumab [I,A].
• Combination 
without platinum: 
Trabectedin + PDL 
[I,A].
• Combi with
platinum: 
Carbo + PDL  [I,A] 
Carbo + GEM [I,A]
Carbo + PAC [I,B] 
• Carbo + GEM + 
Bevacizumab [I,A]
• Evaluate for surgery 
[II,A].
• Combination with 
platinum [I,A]:
Carbo + PLD
Carbo + GEM
Carbo + PAC
Carbo + GEM + 
Bevacizumab [IA]    
• Trabectedin + PLD if 
carbo alergy [I,A].
combination to be superior to single agent PLD in the first recurrence of ovarian cancer. The benefit was restricted to 
patients with a platinum-free interval (PFI) > 6 months, specially in those considered partially platinum-sensitive (PFI 6-
12 months).
* * In patients not suitable for combination chemotherapy. Pegylated liposomal doxorubicin(PLD), Carboplatin (Carbo), 
Gemcitabine (GEM), Paclitaxel (PAC).
Fig. 3 Treatment options in
relapsed ovarian cancer.
(Defined by Progression Free-
Interval)
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Treatment of distinct subgroups defined by PFI
Secondary cytoreduction may be appropriate in selected
patients despite there is no level 1 evidence which dem-
onstrates a survival advantage. The goal of this surgery is
the same as in primary upfront primary surgery. Best
candidates for the survival benefit of this surgery are those
with a long interval of disease free, no ascites at recurrence,
localized disease or few sites of tumor, and complete
resection of disease.
For the majority of patients with recurrent EOC, the
treatment is based only on systemic therapy. Several fac-
tors should be considered in the selection of second-line
therapy in EOC:
• Factors depending on the treatment:
– Response to the last therapy and time since it
finished
– Activity and toxicity of available treatments
– Ease of administration and cost.
• Factors depending on the patient:
– Previous and residual toxicity experienced by the
patient
– Clinical condition and previous medical history
– Preference of the patient.
Figure 3 shows treatment of distinct sub-groups (defined
by PFI).
Treatment of patients with a PFI \6 months
Patients with platinum-resistant relapse used to be candi-
dates for inclusion in clinical trials with new agents. In the
absence of a clinical trial, single-agent therapy without
‘‘platinum’’ is the best palliative option. Several drugs have
shown, in phase III trials, some activity with response rates
(RR) of 10–15 % and median overall survival (OS) of
9–12 months. Some studies have found combination che-
motherapy to be active in patients with a relapse after a PFI
\6 months [1]. However, all these studies show that che-
motherapy combinations do not improve PFS or OS, but
constantly toxicity is significantly higher.
According to these data, in patients with Recurrent OC
and a PFI\6 months, sequential single-agent therapy is the
best palliative option as quality of life is the most important
endpoint [I, A]. A randomized phase III trial evaluating
bevacizumab 15 mg/kg every 3 weeks plus chemotherapy
versus chemotherapy for platinum-resistant recurrent
ovarian cancer [90], provides statistically significant and
clinically meaningful improvement in PFS (3.4 vs.
6.7 months), HR 0.48 (0.38–0.60) and objective response
rate (ORR) versus chemotherapy alone (30.9 vs. 12.6 %).
Strict inclusion criteria minimized the incidence of bev-
acizumab adverse effects. This is the first phase III trial in
platinum-resistant OC to show benefit with a targeted
therapy and improved outcome with a combination versus
monotherapy [90] [I, A].
Treatment of patients with a PFI [12 months
Patients with recurrent disease and a PFI over 12 months
are considered fully platinum sensitive, as they use to
respond to retreatment with a platinum-based regimen. We
have strong evidence, summarized in the Table 8, showing
that a platinum-based combination is associated to a longer
PFS and also OS in comparison to single-agent platinum
chemotherapy [I, A]. As there is no combination that can
be considered superior in terms of efficacy, the selection
between the different options should be based on the tox-
icity profile of the different options. Table 8 also summa-
rizes the most relevant toxicities with each combination
[91–94].
Hypersensitivity can occur during the second-line
treatment. This may occur in up to 25 % of patients; it is
Table 8 Recurrent OC PFI [12 months, two (with platinum) are better than one
Study N Prior 6–12 Months (%)a Treatment PFS HR 95 % CI OS
taxane (%)
ICON 4 [91] 802 43 25 Carboplatin 9 months 0.76 0.66–0.89 24 months
Carboplatin–Pac 12 months 29 months
GEICO 9801 [92] 81 87.20 42.30 Carboplatin 8.4 months 0.54 0.32–0.92 17 months
Carboplatin–Pac 12.2 months –
AGO-EORTC [93] 356 70 40 Carboplatin 5.8 months 0.72 0.58–0.90 17.3 months
Carboplatin–Gem 8.6 months 18 months
CALYPSO [94] 973 35 99 Carboplatin–Pac 9.4 months 0.821 0.72–0.94 –
Carboplatin–PLD 11.3 months
a Rate of patients with a platinum-free interval of 6–12 months
PFS progression-free survival, OS overall survival, HR hazard ratio, 95 % CI 95 % confidence interval
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more likely with carboplatin and usually appears from the
seventh treatment cycle. Reactions may be mild (skin rash)
but sometimes are severe (anaphylactic shock). The rein-
troduction of the drug will depend on the expected benefits
weighed against the potential risks. In such a case, one of
the desensitizing protocols published in the literature
should be followed [1].
A randomized trial of carboplatin–gemcitabine plus
bevacizumab or placebo included 484 patients with a
recurrent ovarian cancer over 6 months after first line of
platinum-based chemotherapy [95]. Patients included
should have measurable disease and the primary endpoint
was PFS as determined by RECIST progression. The
association of bevacizumab increased the median PFS from
8.4 to 12.4 months (HR 0.48, 95 % CI 0.34–0.60) and was
confirmed by an independent radiology committee. Addi-
tionally, the response rate was also higher (78.5 vs. 57.4 %,
p \ 0.0001). The third pre-planned analysis of overall
survival has not shown significant differences (33.4 with
bevacizumab vs. 33.7 with placebo), and it has been
explained more probably for the long post-progression time
and the significant number of chemotherapy lines given
during this period. On the basis of these results, bev-
acizumab was approved for the platinum-sensitive recurrent
ovarian cancer by the EMA (European Medicines Agency).
Treatment of patients with a PFI 6–12 months
Patients relapsing between 6 and 12 months after the last
platinum-based chemotherapy used to have a lower
response to platinum than those considered fully platinum
sensitive (PFI[12 months) and also a shorter PFS and OS.
For this reason, different strategies beyond carboplatin-
based regimens are under investigation on this group of
patients.
One of these strategies is the use of non-platinum-based
regimen, based on the results of the OVA-301 trial [96].
This multinational, multicenter trial assessed the safety and
efficacy of trabectedin plus PLD versus PLD alone in
platinum-sensitive and platinum-resistant patients with
recurrent ovarian cancer. The primary endpoint was PFS.
Patients were randomly assigned to receive a 90-min
infusion of PLD 50 mg/m2 every 4 weeks (n = 330) or a
90-min infusion of PLD 30 mg/m2 followed by a 3-h
infusion of trabectedin 1.1 mg/m2 every 3 weeks
(n = 333). The groups were well matched for baseline
characteristics, with 63–65 % of patients classified as
platinum sensitive (PFI C6 months). The distribution of
patients with PFI of 6–12 months and PFI[12 months was
fairly equal in these groups. PFS was 7.3 months in
patients receiving the combination of PLD and trabectedin
versus 5.8 months for patients who received PLD alone
(HR 0.79, 95 % CI 0.65–0.96, p = 0.0190). Stratifying
results according to platinum-resistant or platinum-sensi-
tive status demonstrated that the benefit is observed only in
platinum-sensitive patients.
A subgroup analysis showed that the group of patients
with a PFI of 6–12 months obtained an increment in OS
when treated with trabectedin and PLD than compared to
PLD monotherapy [97, 98]. This difference was more
evident when platinum was the next regimen used after the
progression of the patient to the trial medication, raising
the hypothesis that a prolongation of the platinum-free
interval by a non-platinum-based regimen could restore the
platinum sensitivity and be beneficial for the patient. This
hypothesis is the background of the randomized clinical
trial INOVATYON (INternational OVArian Cancer
Patients Trial With YONdelis), which includes patients
with recurrent OC and a PFI of 6–12 months and compares
the combination of carboplatin–PLD followed by the reg-
imen selected by the investigator at progression or tra-
bectedin–PLD followed by a platinum-based regimen at
progression.
Based on the above-mentioned sub-analysis, the com-
bination of trabectedin and PLD has been proposed as an
alternative for patients with a PFI of 6–12 months.
Strategies for the future in ovarian cancer
The progress in the treatment of OC will be leaded by a
better understanding of the biology of the disease and the
development of new targeted therapies.
According to the 4th OC Consensus Conference, the
most promising areas appear to be the antiangiogenesis and
the homologous recombination deficiency [2].
Other promising targets currently being studied based on
OC biology include: PI3-kinase and Ras/Raf pathways;
folate receptor; and immune targets/cytokines, notch/
hedgehog and IGF, which all merit further investigation.
The Consensus also stated three important principles:
(1) the necessity of exploring predictive biomarkers to
select the adequate patient for the drugs, (2) one of the
priorities should be to understand the mechanism of
resistance to new drugs, and (3) targeted agents should be
studied both as single agents and in combination based on
preclinical data [2].
A review of all the targets, the preliminary clinical
results and the ongoing clinical trials is beyond the scope of
this article. Figure 4 summarizes the main agents.
However, due to the fact that bevacizumab is the only
targeted therapy available for clinical use in ovarian cancer
right now, it is worth to make some reflections. Specifi-
cally, despite the positive results of ICON-7 and GOG-218,
several questions remain to be answered about the use of
bevacizumab, at least in the front line of ovarian cancer:
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• Is PFS a valid end-point or should it be OS? This is an
important topic but according to the 4th Ovarian Cancer
Consensus Conference, the PFS is the preferred end-
point in first line due to the confounding effect of post-
progression therapy in ovarian cancer. Nevertheless,
OS is still an important endpoint ant it should be
maintained in clinical trials when possible.
• Dose selection of bevacizumab? Unfortunately, we do
not have an answer for this question, as we have
positive results with two different doses (7.5 and
15 mg/kg), without any significant difference in toxic-
ity or a randomized comparison that could help to the
clinician.
• Optimal duration of bevacizumab? In both trials, the
maximum effect was obtained at the moment when
bevacizumab was stopped, and this observation has
generated the hypothesis that a longer duration of
bevacizumab could be associated to a higher benefit.
To explore this interesting clinical question, the AGO
group has launched a trial comparing 15 months of
bevacizumab in the control arm against 30 months in
the experimental arm.
• Other important questions that need to be answered in
ongoing and future clinical trials are about the role of
bevacizumab in second line when it was used in first
line, a well-designed pharmaco-economic analysis and
the validation of predictive biomarkers. Fortunately,
both first line trials were accompanied by an important
translational program seeking for predictive biomarkers
on the use of bevacizumab.
Methodology in clinical trials
A large number of new therapies are being studied in OC,
presenting additional challenges, in terms of identifying
their activity and their place in the treatment. Establishing
Epithelial ovarian cancer
Targets for treatment
Microenvironment
-VEGF: Bevacizumab
VEGF-Trap
-VEGFR: Pazopanib (*,+)
Cediranib (*,+)
Nindetanib(*)
Sorafenib (*)
Sunitinib
Carbozantinib(*)
-Integrins: Volocixumab
-Angiopoietin: AMG386  
Angiogenesis
Immune Cells
-Cytokines: IFN
IL2
-Tregs: Denileukin
Diftitox
Tumour cell
Surface markers
-Folate receptor: Morab 003
EC-17
EC-145
-PDGFR: Imatinib
Dasatinib
Sorafenib (*)
Pazopanib (*,+)
Cediranib (*,+)
Nindetanib (*)
XL 999
G706
-Her-2/neu: Trastuzumab
Pertuzumab
Lapanitib
-EGFR: Erlotinib
Gefitinib
-Integrins: Volocixumab
-CA125: Oregovomab
Abagovomab
Nuclear targets
-ER: Tamoxifen
Arimidex
Examestane
Letrozole
LHRH
-PARP: ABT-888
INO 1001
Intracellular Signaling
-PI3K/AKT: IC486068
Halequinone
PX-316
Perifosine
BX-795
BX-912
BX-320
-mTOR: CCI-779
RAD-001
AP-23573
-Ras-raf: Sorafenib
-PKC: Enzastaurin
-Famesylation: Tipifarnib
(*)= Currently phase II studies are developing
(+)= Currently phase III studies are developing
Fig. 4 Target for OC treatment based on OC biology
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optimal treatment as single agent, or in combination with
chemotherapy, or as maintenance treatment, requires new
approaches to trial design, selection of meaningful end-
points and carefully conducted trials with translational
studies.
A clinical endpoint is a characteristic or variable that
reflects how a patient feels, functions, or survives, while a
surrogate endpoint is a biomarker or endpoint that is
intended to substitute for a clinical endpoint. A good cor-
relate may not make a good surrogate. A surrogate end-
point is expected to predict clinical benefit (or harm), or
lack thereof [99].
The 2010 Gynecologic Cancer InterGroup (GCIG)
consensus statement on clinical trials in OC includes a
review of the latest evidence from high-quality clinical
trials [2].
Appropriate endpoints for clinical trials should reflect
the achievement of clinical benefit, which is defined as
improvement of one or more of the following subjective
and objective endpoints: toxicity, time without symptoms,
patient-reported outcomes (PRO), PFS, overall survival (OS).
Cost effectiveness should be evaluated when feasible [2].
We should assess the meaningful endpoints in different
OC settings for phase III trials. In adjuvant trials for early
disease, RFS (recurrence free survival) is a valid surrogate
for OS. In first line for advance disease, PFS is a valid
surrogate for OS for trials with chemotherapy. As men-
tioned before, PFS is the preferred endpoint because of the
confounding effect of post-progression therapy. However,
when possible, the study should be powered to allow
proper assessment of both PFS and OS. Finally, how the
PFS is defined should be established with regard to method
(CA-125; RECIST) and timing of evaluation.
In platinum-sensitive relapse, if PFS is used as primary
endpoint, trials should be powered for OS as co-primary
endpoint, otherwise OS is the preferred primary endpoint
for phase III trials [2].
In resistant-refractory, we will consider composite
endpoints involving QoL aspects due to clinical relevance
of the patients [2]. Secondary endpoints may include
objective response rate, percent survival at 6 months,
health-related quality of life, PRO, time without symptoms
or toxicity, and pharmacoeconomic analyses. PFS is the
preferred endpoint (over ORR at a time point) and ORR is
not a validated endpoint when testing new agents.
The conference addresses a number of molecular
markers as surrogate outcomes and predictive factors;
however, although most of these markers hold significant
promise, there is no standard molecular profile that must be
included in all trials. It was recommended that the collec-
tion of biological specimens be considered in each and
every clinical trial at predetermined intervals. This recog-
nizes that there are multiple issues to be addressed and
harmonized in the collection of tissues in different juris-
dictions and central analysis [2].
Cooperation in research in Gynecological Oncology
To organize, stimulate and coordinate clinical research
studies on gynecological cancer in general, but especially
on ovarian cancer, multidisciplinary specialist networks
need to be set up which can then form working subgroups
with the participation of oncologists, surgeons, patholo-
gists, pharmacoeconomic specialists, epidemiologists, etc.
Society meetings should promote academic clinical tri-
als, disseminate the results of important trials, and facilitate
the development and coordination of new trials. Finally,
the leadership of our sister societies should meet several
times a year to share information and coordinate educa-
tional programmes. We must continue to work together to
reduce the global burden of gynecological cancer.
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